Neuren reduces outstanding convertible note principal
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Neuren Rights Issue Offer Document (NZ residents)
- Neuren Rights Issue Letter of Offer (Australian residents)
- NEU: Neuren places $3m of rights issue shortfall
- Rett Syndrome pre-IND meeting held with FDA
- Neuren to proceed with oral NNZ2566 trial
Later from Neuren Pharmaceuticals
- Neuren Completes Additional Phase I Study for TBI
- Neuren Initiates NNZ2566 Oral Formulation Development
- Cato strategic partnership and appoints US CMO
- Grant funding for TFF oncology program
- Neuren Starts Phase II Trial of NNZ2566
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals